Results of the three rounds of the Finnish prostate cancer screening trial - The incidence of advanced cancer is decreased by screening

International Journal of Cancer

Volumn 127, Issue 7, 2010, Pages 1699-1705

  Kilpeläinen, Tuomas P ^a,b   Auvinen, Anssi ^b   Määttänen, Liisa ^c   Kujala, Paula ^a   Ruutu, Mirja ^d   Stenman, Ulf Håkan ^d   Tammela, Teuvo L J ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c FINNISH CANCER REGISTRY   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Mass screening; Prostate specific antigen; Prostatic neoplasms; Randomized controlled trials

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ERROR; FALSE POSITIVE RESULT; FINLAND; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; CANCER STAGING; MASS SCREENING; METHODOLOGY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RISK REDUCTION; TIME;

FINLAND; HUMANS; MALE; MASS SCREENING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK REDUCTION BEHAVIOR; TIME FACTORS;

EID: 77956569129     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25368     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
3. Andriole GL, Crawford ED, Grubb RL, III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
4. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685-92.
5. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365-9.
6. Aalen OO. Non parametric inference for a family of counting processes. Ann Stat 1978;6:701-26.
7. Nelson W. Theory and applications of hazard plotting for censored failure data. Technometrics 1972;14:945-66.
8. de Koning HJ, Liem MK, Baan CA, Boer R, Schröder FH, Alexander FE; ERSPC. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial. Int J Cancer 2002;98:268-73.
9. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American cancer society guidelines and issues in cancer screening. CA Cancer J Clin 2009;59:27-41.
10. American Urological Association Guidelines; Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines. cfm, accessed on July 8th, 2009.
11. Roobol MJ, Grenabo A, Schröder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European randomized study of screening for prostate cancer. Gothenburg and. Rotterdam. J Natl Cancer Inst 2007;99:1296-303. (Pubitemid 47398681)
12. Auvinen A, Raitanen J, Moss S, de Koning HJ, Hugosson J, Tammela T, Roobol M, Lilja H, Hakama M. Test sensitivity in the European prostate cancer screening trial: results from Finland. Sweden, and the Netherlands. Cancer Epidemiol Biomarkers Prev 2009;18:2000-5.
13. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:1397-405.
14. Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH. Cancer detection and cancer characteristics in the European randomized study of screening for prostate cancer (ERSPC) - section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007;52:89-97.
15. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, Fine J. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005;97:1248-53.
16. Laurila M, Tammela TL, Auvinen A, Isola J, Visakorpi T, Luukkaala T, Määttänen L, Ruutu M, Ala-Opas M, Mildh M, Martikainen P. Biological aggressiveness of prostate cancer in the Finnish screening trial. Int J Cancer 2009;124:547-52.
17. van der Kwast TH, Ciatto S, Martikainen PM, Hoedemaeker R, Laurila M, Pihl CG, Hugosson J, Neetens I, Nelen V, Di Lollo S, Roobol MJ, Määttänen L, et al. Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European randomized screening study for prostate cancer. Int J Cancer 2006;118:2538-42.
18. Pashayan N, Pharoah P, Neal DE, Hamdy F, Donovan J, Martin RM, Greenberg D, Duffy SW. Stage shift in PSA-detected prostate cancers - effect modification by Gleason score. J Med Screen 2009;16:98-101.
19. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-83.
20. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90. (Pubitemid 34814727)